Released May 9, 2019, after the close
10-Q filed May 9, 2019, 39 days after period end · 0001564590-19-017941
Q1 2019 · 10-Q
Revenue$3.81M$3.81M +230.2% vs Q1 2018+125.0% vs Q4 2018
Net Income-$5.10M-$5.10M N/M vs Q1 2018N/M vs Q4 2018
EPS Diluted-$0.29-$0.29 N/M vs Q1 2018N/M vs Q4 2018
Operating Income-$5,696,000N/M
Operating Cash Flow-$10,924,000N/M
Free Cash Flowderived-$11,005,000—
Margins · derived
Operating margin-149.6%+788.5 pt vs Q1 2018
Net margin-134.0%+789.2 pt vs Q1 2018
What the release said
The release
Same quarter
| Metric | Q1 2019 | Q1 2018 | Q1 2017 | Q1 2016 |
|---|---|---|---|---|
| Revenue | $3.81M | $1.15M | $140.00K | — |
| Net Income | -$5.10M | -$10.64M | -$5.88M | -$5.91M |
| EPS Diluted | -$0.29 | -$0.74 | -$21.60 | -$21.51 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR